Acadia Pharmaceuticals | ACAD - Ebitda



Acadia Pharmaceuticals reported $35.31M in EBITDA for its fiscal quarter ending in June of 2025.


Ebitda Change Date
Acadia Pharmaceuticals USD 35.31M 13.07M Jun/2025
ALKERMES USD 126.53M 105.32M Jun/2025
Alnylam Pharmaceuticals USD 18.83M 13.65M Jun/2025
Biogen USD 1.01B 456.5M Jun/2025
BioMarin Pharmaceutical USD 295.45M 49.49M Jun/2025
Bristol-Myers Squibb USD 3.27B 1.63B Jun/2025
Corcept Therapeutics USD 27.14M 23.27M Jun/2025
Cytokinetics USD -153331000 16.67M Mar/2025
Eisai JPY 8.81B 28.8B Mar/2025
Eli Lilly USD 7.5B 3.34B Jun/2025
Incyte USD 581.52M 358.87M Jun/2025
J&J USD 7.88B 1.76B Mar/2025
Moderna USD -760000000 164M Jun/2025
Neurocrine Biosciences USD 152.9M 121.6M Jun/2025
Pfizer USD 5.32B 889M Jun/2025
Prothena USD -51782000 12.89M Jun/2025
PTC Therapeutics USD 971.14M 970.07M Mar/2025
Sarepta Therapeutics USD 126.42M 416.82M Jun/2025
Ultragenyx Pharmaceutical USD -91344000 35.09M Jun/2025
Vertex Pharmaceuticals USD 1.34B 556.6M Jun/2025